Travere Therapeutics Inc - Asset Resilience Ratio
Travere Therapeutics Inc (TVTX) has an Asset Resilience Ratio of 33.56% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TVTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Travere Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Travere Therapeutics Inc.
Liquid Assets Composition Over Time
This chart breaks down Travere Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Travere Therapeutics Inc (TVTX) investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $186.31 Million | 33.56% |
| Total Liquid Assets | $186.31 Million | 33.56% |
Asset Resilience Insights
- Very High Liquidity: Travere Therapeutics Inc maintains exceptional liquid asset reserves at 33.56% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Travere Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Travere Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Travere Therapeutics Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Travere Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.97% | $229.76 Million | $605.19 Million | -14.58pp |
| 2024-12-31 | 52.54% | $312.17 Million | $594.12 Million | -11.94pp |
| 2023-12-31 | 64.48% | $508.68 Million | $788.91 Million | +6.71pp |
| 2022-12-31 | 57.77% | $388.56 Million | $672.59 Million | +7.92pp |
| 2021-12-31 | 49.85% | $387.13 Million | $776.63 Million | +4.28pp |
| 2020-12-31 | 45.57% | $276.82 Million | $607.44 Million | -10.00pp |
| 2019-12-31 | 55.57% | $336.09 Million | $604.80 Million | +3.58pp |
| 2018-12-31 | 51.99% | $368.67 Million | $709.16 Million | +13.31pp |
| 2017-12-31 | 38.67% | $201.24 Million | $520.35 Million | -2.23pp |
| 2016-12-31 | 40.91% | $214.87 Million | $525.28 Million | +3.47pp |
| 2015-12-31 | 37.43% | $191.80 Million | $512.40 Million | +30.38pp |
| 2014-12-31 | 7.05% | $9.56 Million | $135.47 Million | +6.41pp |
| 2013-12-31 | 0.65% | $132.99K | $20.50 Million | -- |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more